Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Regeneron Pharmaceuticals
Scientific Title
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma